- Board of Directors
Dr. David M. Goldenberg founded Immunomedics in July 1982, and has served continuously since that time as the Chairman of our Board of Directors. He also currently serves as our Chief Scientific Officer and Chief Patent Officer, having been our Chief Medical Officer from July 2007 to December 2014, Chief Strategic Officer from July 2003 to July 2007. Dr. Goldenberg previously served as our Chief Executive Officer from July 1982 through July 1992, from February 1994 through May 1998 and from July 1999 through March 2001. He also serves as Chairman of the Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics.
Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg (Germany) School of Medicine (M.D.). He has written or co-authored approximately 1,700 journal articles, book chapters and abstracts on cancer research, detection and treatment, and has researched and written extensively in the area of radioimmunodetection and radioimmunotherapy using radiolabeled antibodies.
Dr. Goldenberg was President and a Trustee of the Center for Molecular Medicine and Immunology (“CMMI”), an independent non-profit research center, and its clinical unit, the Garden State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an “Outstanding Investigator Grant” award from the National Cancer Institute for his work in radioimmunodetection, and in 1986 he received the New Jersey Pride Award in Science and Technology.
Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology and in 2002, the Elis Bervin Lectureship and Medal from the Swedish Medical Society and the Swedish Oncology Society for his contributions to the development of radiolabeled monoclonal antibodies used in the imaging and treatment of cancer. The International Society for Oncodevelopmental Biology and Medicine named Dr. Goldenberg the co-recipient of the 1994 Abbott Award. In 2005, he received the Paul Aebersold Award from the Society of Nuclear Medicine and was named the Inventor of the Year by the Research and Development Council of New Jersey. Maryann Liebert Inc., publisher of Genetic Engineering News, nominated Dr. Goldenberg in 2006 for the Forbes Enterprise Award for outstanding achievements in the scientific community.
Mr. Jason Aryeh has more than 20 years of equity investment experience focused on the life sciences industry. He is the Founder and Managing General Partner of JALAA Equities, LP, a private, activist-oriented hedge fund focused on the life-sciences sector, and has served in such capacity since 1997. He is Chairman of the Board of Novelion Therapeutics, Inc. (NASDAQ: NVLN). He also serves as a member of the Boards of Directors of Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). Mr. Aryeh also serves as a consultant, focused on the enhancement of shareholder value, for Derma Sciences, Inc. (NASDAQ: DSCI). Furthermore, Mr. Aryeh is active in a respected healthcare charity, serving on the Cystic Fibrosis Foundation’s Therapeutics Board since 2011. Mr. Aryeh earned a B.A. in economics, with honors, from Colgate University, and is a member of the Omnicron Delta Epsilon Honor Society in economics.
Dr. Geoffrey Cox is a seasoned executive with more than 16 years of experience in Chairman and CEO roles at publicly traded life sciences companies and more than four decades of overall industry experience. Dr. Cox is currently principal of Beacon Street Advisors LLC, which provides strategic, operational and organization advisory services and interim senior management support to life sciences companies. Most recently he served as interim CEO of QLT Inc. (NASDAQ: NVLN), a publicly traded ophthalmology company. Previously he was a partner at Redsky Partners LLC Consulting, and prior to that he served for nearly a decade as Chairman, President and CEO of GTC Biotherapeutics Inc. (now known as rEVO Biologics), where he successfully repositioned the Company and oversaw the development of multiple human therapeutic proteins based on a novel manufacturing technology and the first regulatory product approval based on that technology. Prior to that he served as Chairman, President and CEO of Aronex Pharmaceuticals, Inc. Earlier in his career, Dr. Cox held various roles at Genzyme U.K. and Genzyme Corporation over more than 13 years, concluding his service as Executive Vice President responsible for Genzyme’s General Division worldwide manufacturing operations and infrastructure, and for the pharmaceuticals, diagnostics and genetics business units. He began his career at Gist Brocades, NV. Dr. Cox serves as a member of the Boards of Directors of Aviragen Therapuetics Inc. (NASDAQ: AVIR), Novelion Therapeutics, Inc. (NASDAQ: NVLN) and Lakewood-Amedex Inc.
Mr. Robert Forrester has decades of relevant experience at both private and public life sciences companies, as well as business development, M&A and financial expertise. He currently serves as a director and Chief Executive Officer of Verastem, Inc. (NASDAQ: VSTM) following various leadership roles including President and Chief Operating Officer. Prior to joining Verastem, Mr. Forrester served as Chief Operating Officer of Forma Therapeutics, Inc. and previously served as Interim President and Chief Executive Officer of CombinatoRx, Inc., and as its Executive Vice President and Chief Financial Officer. He has also served as Senior Vice President of Finance and Corporate Development at Coley Pharmaceuticals Group, Inc. Prior to that, Mr. Forrester was a managing director of the Proprietary Investment Group at MeesPierson, and has also held roles at the investment banks BZW (now Barclays Capital) and UBS in the corporate finance groups undertaking M&A and public and private finance transactions. He began his career as a lawyer in England prior to entering investment banking.
Mr. Brian A. Markison is a Healthcare Industry Executive at Avista Capital Partners, a leading private equity firm. Previously, Mr. Markison served as the President, Chief Executive Officer and a member of the Board of Directors of Fougera Pharmaceuticals, a company created from the acquisition of Nycomed A/S by Takeda Pharmaceuticals. Effective July 23, 2012, Fougera Pharmaceuticals was acquired by Novartis AG. From 2004 to 2011, he was President and Chief Executive Officer of King Pharmaceuticals, Inc. and elected Chairman of the Board of Directors in 2007. Effective February 28, 2011, King Pharmaceuticals, Inc. was acquired by Pfizer Inc. Prior to joining King Pharmaceuticals, Mr. Markison was the President of Oncology, Virology and Oncology Therapeutics Network Business at Bristol-Meyers Squibb. During his 22-year career at Bristol-Meyers Squibb, he distinguished himself in the areas of sales, marketing, international and domestic general management positions. Mr. Markison also serves as the Chairman of the Board of Directors for Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and a Director for PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats.
Mr. Bob Oliver has more than 25 years of experience in the pharmaceutical industry, including in General Management and executive level experience helping world-renowned global pharmaceutical companies expand commercial operations. He currently serves as President and CEO of Otsuka America Pharmaceutical, Inc., (“OAPI”) and previously held roles at OAPI of Chief Operating Officer; Senior Vice President of Sales and Marketing and as President. Mr. Oliver built OAPI’s commercial capabilities, working with Lundbeck to launch ABILIFY MAINTENA (aripiprazole) and led the transfer of ABILIFY® (aripiprazole) commercial and medical responsibilities from Bristol-Myers Squibb to OAPI. During Mr. Oliver’s leadership, ABILIFY® grew to the number-one selling pharmaceutical in the U.S. Prior to joining OAPI, Mr. Oliver was Vice President & Global Business Manager for Oncology at Wyeth Pharmaceuticals. He also served as Senior Vice President of Primary Care and Commercial Operations at Wyeth where he oversaw sales and commercial operations in the U.S. and general management in Puerto Rico. Prior to Wyeth Mr. Oliver spent 16 years with Johnson & Johnson in roles of increasing responsibility. Mr. Oliver has served as Chairman of the Board for Otsuka Canada Pharmaceuticals, Inc. since 2014.
Ms. Cynthia L. Sullivan has been employed by Immunomedics since October 1985, and has served as our President and Chief Executive Officer since March 2001. She previously served as the Company’s President from December 2000 to March 2001 and as Executive Vice President and Chief Operating Officer from June 1999 to December 2000. Prior to joining Immunomedics, Ms. Sullivan was employed by Ortho Diagnostic Systems, Inc., a subsidiary of Johnson & Johnson.
Ms. Sullivan’s educational background includes: a B.S. from Merrimack College, North Andover, Massachusetts, followed by a year of clinical internship with the school of Medical Technology at Muhlenberg Hospital, Plainfield, New Jersey, resulting in a M.T. (ASCP) certification in 1979. Ms. Sullivan completed a M.S. degree in 1986 from Fairleigh Dickinson University, where she also received her M.B.A. in December 1991.
Ms. Sullivan also serves as President of our majority owned subsidiary, IBC Pharmaceuticals, Inc. From September 2002 to July 2007, Ms. Sullivan served as a member of the Board of Directors of Digene Corp., a company that develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. Effective July 30, 2007 Digene Corp was merged with Qiagen N.V. As of May 2009, Ms. Sullivan also serves as a member of Board of Trustees for the HealthCare Institute of New Jersey, a trade association for the research-based pharmaceutical and medical technology industry in New Jersey.